Oral Micronized Progesterone Cost in Connecticut (2026)

What Does Oral Micronized Progesterone Actually Cost in Connecticut?

The price depends entirely on which version you fill and where you fill it. Brand-name Prometrium carries a manufacturer list price of $180 per month, but generic oral micronized progesterone averages $45 per month across Connecticut retail pharmacies in 2026, based on cash-pay pricing at chains like CVS, Walgreens, and independent pharmacies statewide.

Connecticut residents have three pricing tiers to consider. The brand product (Prometrium, originally manufactured by Solvay, now marketed by AbbVie) sits at the top. Generic micronized progesterone capsules from manufacturers like Teva and Mylan occupy the middle. Compounded progesterone from a licensed 503A pharmacy in Connecticut runs the lowest, at roughly $25 per month.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875) established that oral micronized progesterone at 200 mg daily for 12 days per cycle provided effective endometrial protection without erasing the HDL benefits of conjugated equine estrogens 1. That study gave micronized progesterone its clinical foundation, and the FDA subsequently approved Prometrium for use in combination with estrogen to prevent endometrial hyperplasia 2.

These price differences matter clinically because hormone replacement therapy is typically a long-term commitment. A woman starting progesterone at age 52 who continues therapy for five years will spend between $1,500 and $10,800 over that period depending on the formulation she fills. That spread can determine whether she stays on therapy or stops prematurely.

For context, a 2020 analysis published in Menopause found that out-of-pocket cost was the single most cited reason women discontinued HRT within the first year, ahead of side effects 3. Connecticut's relatively competitive generic market helps, but the state's cost of living means patients often feel even moderate pharmacy bills.

Generic vs. Brand Prometrium: Is There a Clinical Difference?

No meaningful clinical difference exists between generic oral micronized progesterone and brand Prometrium for the vast majority of patients. Both contain micronized progesterone in peanut oil, both are taken as oral capsules, and both meet FDA bioequivalence standards.

The FDA requires that generic drugs demonstrate bioequivalence within an 80% to 125% confidence interval for AUC (area under the curve) and Cmax (peak concentration) compared to the reference product 4. In practice, most approved generics fall within 3% to 5% of the brand on these pharmacokinetic parameters.

One consideration: patients with peanut allergies cannot use either brand or standard generic micronized progesterone capsules because the active ingredient is suspended in peanut oil. This is explicitly noted in the Prometrium prescribing information 2. For these patients, a compounded formulation using an alternative oil base becomes medically necessary, not just a cost-saving choice.

The $135 per month gap between brand ($180) and generic ($45) in Connecticut adds up to $1,620 annually. Unless a patient has a specific adverse reaction to a generic filler ingredient, generic micronized progesterone is the rational starting point.

Connecticut Medicaid Coverage for Oral Micronized Progesterone

Connecticut Medicaid (HUSKY Health) covers oral micronized progesterone with prior authorization. The prior authorization requirement means your prescriber must document a clinical reason for the prescription before Medicaid will pay.

For endometrial protection during HRT, this documentation is straightforward. The standard clinical rationale: the patient is on estrogen therapy and has an intact uterus, requiring progesterone to prevent endometrial hyperplasia. The Endocrine Society's 2015 clinical practice guideline on menopause management states that "progestogen therapy is recommended for all postmenopausal women with a uterus who are treated with systemic estrogen" 5. That recommendation alone typically satisfies the PA requirement.

Connecticut's Department of Social Services publishes a preferred drug list (PDL) that is updated quarterly. Generic micronized progesterone has maintained preferred status on the CT Medicaid PDL, which means lower co-pays and simpler approval pathways compared to non-preferred alternatives like medroxyprogesterone acetate in some dosing configurations.

Patients enrolled in HUSKY A (low-income adults), HUSKY B (children), HUSKY C (elderly and disabled), or HUSKY D (Affordable Care Act expansion adults) all access pharmacy benefits through the same PDL, though co-pay amounts differ by plan tier. Most Medicaid enrollees in Connecticut pay $0 to $3 per generic prescription fill.

One practical tip: if a prior authorization is denied on the first attempt, Connecticut Medicaid allows a prescriber-initiated appeal. According to the North American Menopause Society (NAMS) 2022 position statement, micronized progesterone is preferred over synthetic progestins for most HRT regimens due to its more favorable cardiovascular and breast safety profile 6. Citing this guideline in an appeal letter strengthens the case significantly.

Compounded Progesterone in Connecticut: Legal, Affordable, and Sometimes Necessary

Compounded progesterone is legal in Connecticut through licensed 503A pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription 7.

The price advantage is real. At approximately $25 per month, compounded progesterone costs roughly 44% less than generic retail and 86% less than brand Prometrium. Connecticut has multiple licensed compounding pharmacies, concentrated in the Hartford, New Haven, and Fairfield County areas.

Compounding becomes clinically appropriate in several scenarios. Peanut allergy (as noted above) is the clearest indication. Custom dosing is another. The FDA-approved capsules come in 100 mg and 200 mg strengths only. A patient who needs 150 mg, or who requires a formulation without specific dyes or fillers present in commercial products, may benefit from a compounded preparation.

The tradeoff: compounded drugs do not undergo the same FDA batch-testing and bioequivalence review as commercially manufactured generics. A 2001 FDA survey found that 34% of compounded products tested failed one or more quality standards, compared to less than 2% of commercially manufactured drugs 8. Connecticut's Department of Consumer Protection oversees pharmacy compounding within the state, and the Board of Pharmacy conducts inspections, but the level of regulatory scrutiny is inherently lighter than for FDA-approved products.

Dr. JoAnn Pinkerton, former executive director of NAMS, has noted: "When an FDA-approved micronized progesterone product is available at an accessible price, it should be the first choice. Compounding fills an important gap for patients who cannot tolerate commercial formulations, but it is not a wholesale replacement for regulated products" 6.

For Connecticut residents specifically, insurance plans (including Medicaid) typically do not cover compounded prescriptions. This means the $25 per month is an out-of-pocket cost regardless of your insurance status. Patients with good insurance coverage for generic progesterone may actually pay less through their pharmacy benefit ($0 to $10 co-pay) than they would for a compounded version.

Insurance Coverage Beyond Medicaid: What Connecticut Plans Typically Cover

Most commercial insurance plans sold on Access Health CT (Connecticut's ACA marketplace) and most employer-sponsored plans cover generic oral micronized progesterone. The Affordable Care Act requires coverage of FDA-approved preventive services for women, and while progesterone itself is not classified as a contraceptive, its role in HRT means it typically lands on formularies as a standard covered medication.

Connecticut-specific insurers and their general formulary patterns for oral micronized progesterone:

Anthem Blue Cross Blue Shield CT covers generic micronized progesterone on Tier 1 (preferred generic) for most commercial and marketplace plans. Co-pays range from $0 to $15 per 30-day fill.

ConnectiCare includes generic micronized progesterone on its preferred drug list. ConnectiCare plans sold through Access Health CT typically carry $5 to $20 generic co-pays.

Aetna (headquartered in Hartford) covers generic progesterone across its commercial book of business. Many Aetna plans available in Connecticut place it on Tier 1.

UnitedHealthcare plans available in CT carry generic micronized progesterone on formulary with standard generic tier co-pays.

Brand Prometrium is typically placed on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), with co-pays ranging from $35 to $75 per month. Given the clinical equivalence of generic formulations, step therapy protocols at most Connecticut insurers require a trial of generic before covering brand.

A 2023 study in the Journal of Women's Health found that formulary restrictions on HRT medications led to a 23% higher rate of therapy discontinuation compared to unrestricted access 9. Connecticut patients who encounter step therapy or prior authorization barriers should ask their prescriber to file the necessary paperwork promptly, because gaps in progesterone therapy while on estrogen leave the endometrium unprotected.

How to Get the Lowest Price in Connecticut

Start with your insurance formulary. If your plan covers generic micronized progesterone at a $0 to $15 co-pay, that is likely your best price. Check your plan's preferred pharmacy network, because using a non-preferred pharmacy can double or triple your co-pay.

If you are uninsured or your plan does not cover progesterone, compare these options:

GoodRx and similar discount cards frequently bring generic micronized progesterone below $30 per month at Connecticut pharmacies. Prices vary by pharmacy. Costco and independent pharmacies tend to offer the lowest discount-card pricing in the state, while CVS and Walgreens often run slightly higher.

Manufacturer savings programs exist for brand Prometrium but are typically restricted to commercially insured patients and exclude Medicare and Medicaid beneficiaries. The savings can bring brand co-pays down to $25 to $35 per month, but generic at $45 cash-pay (or less with a discount card) is still more economical for most patients.

Mail-order pharmacies through your insurer often provide a 90-day supply for the price of two co-pays. For a medication taken nightly on a continuous basis, 90-day fills reduce both cost and the inconvenience of monthly refills.

503A compounding at $25 per month remains the floor price in Connecticut for patients paying entirely out of pocket. Verify that the pharmacy is licensed by the Connecticut Department of Consumer Protection and request a certificate of analysis for the batch if you want to confirm potency.

Patient assistance programs: AbbVie (which markets Prometrium) operates a patient assistance program for uninsured patients who meet income criteria, typically at or below 200% of the federal poverty level. Eligibility details and application forms are available through AbbVie's patient support website.

Telehealth Access for Connecticut Residents

Connecticut permits telehealth prescribing of oral micronized progesterone. The state's telehealth parity law (Connecticut Public Act 15-88, updated in subsequent legislative sessions) requires insurers to cover telehealth visits at the same rate as in-person visits and does not impose geographic restrictions on the patient's location within the state.

For HRT management, telehealth is particularly practical. After an initial evaluation (which may include blood work for estradiol, FSH, and a comprehensive metabolic panel), ongoing progesterone management involves symptom assessment and occasional lab monitoring. Neither requires a physical exam at every visit.

Connecticut-based telehealth platforms and national platforms licensed in CT (including HealthRX) can prescribe oral micronized progesterone and send the prescription electronically to any Connecticut pharmacy. The DEA does not classify progesterone as a controlled substance, so there are no additional telehealth prescribing restrictions beyond standard practice requirements.

A 2021 survey of menopause specialists published in Menopause reported that 78% of HRT management visits could be conducted effectively via telehealth without compromising clinical outcomes 10. For Connecticut patients in rural areas (Litchfield County, parts of Windham County) where the nearest menopause specialist may be 45 to 60 minutes away, telehealth removes a meaningful barrier to consistent therapy.

Continuous vs. Cyclic Dosing and How It Affects Cost

The dosing schedule directly affects your monthly cost. Continuous dosing (100 mg nightly, every night) uses 30 capsules per month. Cyclic dosing (200 mg nightly for 12 to 14 days per month) uses 12 to 14 capsules per month but at double the strength.

At generic cash-pay pricing in Connecticut, continuous 100 mg dosing and cyclic 200 mg dosing land in a similar cost range ($40 to $50 per month) because 200 mg capsules cost roughly twice the per-unit price of 100 mg capsules. The PEPI trial used the cyclic protocol (200 mg for 12 days per cycle), which remains one of the best-studied regimens 1.

Continuous dosing tends to eliminate monthly withdrawal bleeding after the first few months, which many postmenopausal women prefer. Cyclic dosing produces a predictable monthly withdrawal bleed. The choice between them is clinical, not primarily financial, but patients should understand that switching protocols may change their pharmacy cost slightly.

For compounded progesterone, the cost difference between regimens may be more pronounced because compounding pharmacies often price by the total amount of active ingredient dispensed. Discuss both the clinical rationale and the cost implications with your prescriber before selecting a regimen.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on HRT notes that both continuous and cyclic micronized progesterone regimens provide adequate endometrial protection when dosed appropriately 11.